Search results
Results From The WOW.Com Content Network
[9] [17] HER2-positive breast cancers are well established as being associated with increased disease recurrence and a poor prognosis compared with other identifiably genetically distinct breast cancers with other known, or lack thereof, genetic markers that are thought to be associated with other breast cancers; however, drug agents targeting ...
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
In several stable cell lines, it is possible to induce specific estrogen-related proteins. For example, in the human MCF-7 breast cancer cell line the protein pS2 is strongly up-regulated by estrogen. Induction of the pS2 protein can be detected already one hour after estrogen, or a given compound acting as an estrogen, is added to the cells.
The estrogen receptor test (ERT) is a laboratory test to determine whether cancer cells have estrogen receptors.This information can guide treatment of the cancer. [1]The test uses immunohistochemical techniques on the estrogen receptor (ER).
Most cancer isn't caused by BRCA mutations — they account for 5 percent to 10 percent of breast cancers and 15 percent of ovarian cancers — so the gene tests aren't for everyone. But mutations ...
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance.
These treatments are now some of the most effective adjuvant treatments of breast cancer. Estrogen receptor positive (ER+) cancer cells depend on estrogen for their growth, so they can be treated with drugs to reduce either the effect of estrogen (e.g. tamoxifen) or the actual level of estrogen (e.g. aromatase inhibitors), and generally have a ...
The assay has a very good sensitivity (detection limit for 17β-estradiol in the YES assay about 5 x 10 −12 M or 1.4 ng/L), [1] [2] [4] and the microplate format requires only small amounts of sample. Analysis of native aqueous samples, concentrated environmental samples and chemicals or mixtures in solvents like ethanol or DMSO is possible.